2020
Acute flaccid myelitis: cause, diagnosis, and management
Murphy O, Messacar K, Benson L, Bove R, Carpenter J, Crawford T, Dean J, DeBiasi R, Desai J, Elrick M, Farias-Moeller R, Gombolay G, Greenberg B, Harmelink M, Hong S, Hopkins S, Oleszek J, Otten C, Sadowsky C, Schreiner T, Thakur K, Van Haren K, Carballo C, Chong P, Fall A, Gowda V, Helfferich J, Kira R, Lim M, Lopez E, Wells E, Yeh E, Pardo C, group A, Salazar-Camelo A, Mithal D, Wilson-Murphy M, Bauer A, Watkins C, Abzug M, Dominguez S, Press C, Yang M, Ahsan N, Ramos-Platt L, Tiongson E, Seruya M, Tilton A, Katz E, Kirschen M, Shah A, Ulloa E, Yum S, Mondok L, Blaufuss M, Rosenfeld A, Vargas W, Zucker J, Yeshokumar A, Navis A, Chao K, Hagen K, Melicosta M, Porter C, Tunney M, Scheuermann R, Duggal P, Pekosz A, Bayliss A, Moore M, Belzberg A, Bembea M, O'Brien C, Riggs R, Nance J, Milstone A, Rice J, Garcia-Dominguez M, Flanagan E, Tillema J, Bosques G, Bhatia S, Gordon-Lipkin E, Deike D, Revivo G, Zlotolow D, deFiebre G, Lazerow P, Lotze T, Bitnun A, Davidge K, Vajsar J, Moore A, Konersman C, Nash K, Strober J, Gupta N, Chiu C, Sweeney M, Jackson W, Simon D, Thakkar K, Cheng J, Luce J, Das S, Vogt M, Vu N, Gofshteyn J, Makhani N, Patel P. Acute flaccid myelitis: cause, diagnosis, and management. The Lancet 2020, 397: 334-346. PMID: 33357469, PMCID: PMC7909727, DOI: 10.1016/s0140-6736(20)32723-9.Peer-Reviewed Original ResearchConceptsAcute flaccid myelitisNon-polio enterovirus infectionMajor public health challengeAcute neurological illnessCerebrospinal fluid characteristicsPolio-like illnessSubstantial residual disabilityProfound muscle weaknessLong-term outcomesTargeted therapeutic approachesPublic health challengeLong-term rehabilitationResidual disabilityAcute phaseClinical featuresClinical presentationEnterovirus infectionImmunological featuresMuscle weaknessNeurological illnessTherapeutic approachesHost-virus interactionsPathogen factorsHealth challengesDiagnosis
2018
1901. Safety, Tolerability, and Efficacy of Fluoxetine as an Antiviral for Enterovirus D68 Associated Acute Flaccid Myelitis: A Retrospective Multicenter Cohort Study
Messacar K, Sillau S, Hopkins S, Otten C, Wilson-Murphy M, Wong B, Santoro J, Treister A, Tokhie H, Torres A, Zabrocki L, Glanternik J, Hurst A, Martin J, Schreiner T, Makhani N, DeBiasi R, Kruer M, Tremoulet A, Van Haren K, Desai J, Benson L, Gorman M, Abzug M, Tyler K, Dominguez S. 1901. Safety, Tolerability, and Efficacy of Fluoxetine as an Antiviral for Enterovirus D68 Associated Acute Flaccid Myelitis: A Retrospective Multicenter Cohort Study. Open Forum Infectious Diseases 2018, 5: s546-s546. PMCID: PMC6254028, DOI: 10.1093/ofid/ofy210.1557.Peer-Reviewed Original ResearchAcute flaccid myelitisFluoxetine-treated patientsSerious adverse eventsMulticenter cohort studyEfficacy of fluoxetineEV-D68Cohort studyInitial examinationSevere paralysisRetrospective multicenter cohort studyPoor long-term outcomesAdverse effectsDose of fluoxetinePropensity-adjusted analysisLong-term disabilityLong-term outcomesPotential antiviral therapiesUntreated controlsAdverse eventsMost patientsEfficacy signalsPrimary outcomeAntiviral therapyStudy criteriaEffective therapySafety, tolerability, and efficacy of fluoxetine as an antiviral for acute flaccid myelitis
Messacar K, Sillau S, Hopkins SE, Otten C, Wilson-Murphy M, Wong B, Santoro JD, Treister A, Bains HK, Torres A, Zabrocki L, Glanternik JR, Hurst AL, Martin JA, Schreiner T, Makhani N, DeBiasi RL, Kruer MC, Tremoulet AH, Van Haren K, Desai J, Benson LA, Gorman MP, Abzug MJ, Tyler KL, Dominguez SR. Safety, tolerability, and efficacy of fluoxetine as an antiviral for acute flaccid myelitis. Neurology 2018, 92: e2118-e2126. PMID: 30413631, PMCID: PMC6512883, DOI: 10.1212/wnl.0000000000006670.Peer-Reviewed Original ResearchConceptsAcute flaccid myelitisSerious adverse eventsFluoxetine-treated patientsEfficacy of fluoxetineEV-D68Initial examinationPoor long-term outcomesImproved neurologic outcomeMulticenter cohort studyClass IV evidenceAdverse effect ratesDose of fluoxetinePropensity-adjusted analysisLong-term outcomesUnexposed patientsNeurologic outcomeUntreated patientsAdverse eventsCohort studyPrimary outcomeUS patientsStudy criteriaEnterovirus D68PatientsEffect rate
2016
International Pediatric MS Study Group Global Members Symposium report
Wassmer E, Chitnis T, Pohl D, Amato MP, Banwell B, Ghezzi A, Hintzen RQ, Krupp LB, Makhani N, Rostásy K, Tardieu M, Tenembaum S, Waldman A, Waubant E, Kornberg AJ. International Pediatric MS Study Group Global Members Symposium report. Neurology 2016, 87: s110-s116. PMID: 27572855, PMCID: PMC10688073, DOI: 10.1212/wnl.0000000000002880.Peer-Reviewed Original ResearchConceptsPediatric multiple sclerosisMultiple sclerosisInternational Pediatric Multiple Sclerosis Study GroupMultiple Sclerosis Study GroupOptimal vitamin D intakeEarly-onset multiple sclerosisNewer MS agentsAcute disseminated encephalomyelitisVitamin D intakeVitamin D deficiencyChildhood multiple sclerosisLong-term outcomesDrug treatment optionsDiverse patient samplesDifferentiation of MSEffective cognitive rehabilitationD intakeDisseminated encephalomyelitisD deficiencyNeuroinflammatory disordersNeuromyelitis opticaMS riskTreatment optionsMS outcomesClinical trials